Direct-to-consumer advertising of prescription medications: what the Canadian medical trainee needs to know

Michael D. Elfassy,¹ Sharef Danho,¹ Alexander Adibfar,¹ Joel Lexchin¹,²,³

¹Faculty of Medicine, University of Toronto, Ontario, Canada
²Faculty of Health, York University, Ontario, Canada
³Emergency Department, University Health Network, Ontario, Canada

Published: July 24, 2019
CMEJ 2019, 10(3):e113-e116 Available at http://www.cmej.ca

You are a medical student in clinic asked to see a 42-year-old man with a past medical history of anxiety. He is presenting with concerns about progressive balding and weight gain. Recently, he came across an internet advertisement suggesting his symptoms may be linked to a low testosterone level. He asks you to provide him with a testosterone prescription. What should medical trainees know about advertising of pharmaceutical products to help patients assess the quality of the information that they have received?

Current Canadian Regulations

Under the Food and Drug Regulations in Canada, Direct-to-Consumer Advertising of Prescription Medications (DTCA) is generally prohibited.¹ However, for a variety of reasons, Canadians are increasingly exposed. A review of complaints about DTCA to Health Canada shows that through loopholes in the interpretation of legislation and poor enforcement by Health Canada, pharmaceutical companies have used a variety of different tactics to advertise their products.² One of them is “reminder ads” wherein companies can advertise their brand without naming the purpose of their product, simply requesting consumers to “ask your doctor.” Another strategy termed “help seeking” urges people to visit their doctor to discuss a certain medical condition, without identifying the brand or product. In reality, the pharmaceutical industry combines these maneuvers with blatant violations of regulations, knowing the profit benefit outweighs any possible sanctions or fines. A Canadian example is Diane-35, a drug approved for treatment of severe acne, but where the company used marketing techniques that implied it could be used for off-label contraception and suffered few repercussions for doing so.
In an increasingly globalized world, borders are in many ways beginning to fade. This holds especially true for DTCA, through which broadcast and online use could expose consumers to advertisements that are not bound by Canada’s regulation. Many Canadians already watch US television broadcasts, which contain many poorly-regulated pharmaceutical advertisements. With digital DTCA on the rise and regulatory responses several steps behind, online platforms are a popular medium for industry investments. Expenditure on internet-based DTCA is growing, whereas all other categories have been experiencing steady expenditure declines, suggesting a strategic shift in keeping with the evolution of digital health. More than ever, Canadians are vulnerable to DTCA, and our physicians must be trained to know how to respond when patients make requests based on ads that they have seen.

Evidence regarding DTCA

While it has been suggested that DTCA may have benefits such as identifying and encouraging treatment for diseases, improving medication compliance, and promoting health education, the bulk of prevailing evidence indicates that these effects are speculative and do not justify harms to public health. DTCA misleads consumers by obscuring side effects and harms, concealing details about products that may put them in a negative light, and instead presenting information to cast products or health conditions of interest in a positive way. Patients who encounter these biased advertisements are likely to present to their physicians with questions and requests, and physicians in turn are more likely to order tests or prescribe medications consistent with the advertising. This can lead to overprescribing, disease mongering, unnecessary medication use, and suboptimal treatment, all of which could have dangerous consequences.

What is taught in medical school about DTCA

To our knowledge, no Canadian medical school dedicates a formalized curriculum component specific to DTCA. However, Canadian medical schools do have policies towards conflicts of interest; these govern direct interactions between students and pharmaceutical companies as well as indirect interactions between students and lecturers who have a relationship with pharmaceutical companies. These policies, however, range widely in comprehensiveness across the medical schools – within Canada, different medical schools afford varying levels of protection to students about conflicts of interest that may impact the education that they are receiving.

Taken together, this lack of a strong, uniform focus on policies about conflicts of interest suggests that any teaching regarding DTCA is currently insufficient and that the content is variable among, and likely even within, schools. This is a cause for concern because medical students will likely encounter DTCA early in medical school while interacting with patients. For example, students are frequently reminded that their future patients will likely have “Googled” their symptoms prior to an appointment. Up to 70% of Canadians search their medical symptoms online prior to seeing a doctor. If this is the case, patients will have undoubtedly been subjected to DTCA, as eDTCA is one of the fastest growing forms of DTCA. Data tracking is a growing phenomenon and is reshaping the advertising field entirely. As such, internet DTCA is more customized than ever, with advertisements tailored to patients’ specific internet browsing history – one click at a time.

Revisiting our introductory case

Does the case presented above in the introduction warrant testosterone investigation? A 2015 Canadian clinical practice guideline on testosterone deficiency and management does not provide a clear answer. When clinical guidelines are unclear or potentially ambiguous, physicians can be swayed in favour of marketed/advertised products, especially in the face of interest from a patient. This 42-year-old patient’s symptoms of weight gain and balding could be explained by a host of medical, environmental, and genetic factors. In the case of testosterone advertising in the US between 2000 and 2011, DTCA was associated with an increase of more than 250% in testosterone prescriptions for males. Testosterone prescriptions were often initiated for non-specific symptoms and even when patients did not meet the classical diagnostic criteria for hypogonadism. Additionally, physicians often deviated from established clinical guidelines by prescribing testosterone without prior serum testing. Like most other drugs, testosterone is not an inert substance and has been associated with adverse outcomes including myocardial infarction.
and stroke.\textsuperscript{16} We should therefore always remain vigilant about our prescribing practices, an approach medical students need to learn.

**What medical trainees should know**

In the situation where a patient asks about an advertised pharmaceutical product, the medical trainee should remember a useful mnemonic, “DTCA” to structure their approach.

**D – Deliberate**

Take a step back and consider how DTCA can influence your own prescribing practices. Be wary that interactions with pharmaceutical companies have been consistently shown to alter the prescribing patterns of physicians, despite the majority denying the capacity to be influenced.\textsuperscript{17}

**T – Tune in**

Use a patient-centred stance to actively listen to the patient and explore the underpinnings of their request. A strong patient-physician relationship is critical in promoting a candid environment where patients will feel comfortable in discussing and learning about the contents of DTCA.

**C – Counsel**

Counsel the patient using an objective approach, taking into consideration the potential benefits, harms, and side effects. Explain that healthcare providers have a fiduciary duty to patients alone, and that pharmaceutical companies do not.

**A – Advise**

Offer your perspective and suggest alternative options to present the patient with the necessary information to make an informed decision. After all, the majority of patients want their physicians to help them in understanding the contents of DTCA.\textsuperscript{18}

When a patient requests a medication or test that is not in their best interest, it is most advantageous to use strategies that reinforce and validate your patient, while also negotiating the most suitable option. First is the “substitution strategy,” which reframes the diagnosis or offers an alternative treatment. If this fails, the “contingency strategy” can offer a trial of the evidence-based treatment strategy with an agreed-upon definition of success, while agreeing to switch to the patient’s preference after a period of time if the evidence-based treatment is unsuccessful.\textsuperscript{19}

**Call to educators**

Integration of an approach to a patient with questions about diagnosis and treatment generated by DTCA into all levels of medical training is increasingly important. The same principles hold true for medical devices, genetic testing, and other health products that are directly advertised to patients.

Conflicts of interest: Michael D. Elfassy, Sharef Danho, and Alexander Adibfar have no conflicts of interest to disclose. In 2015-2018, Joel Lexchin was a paid consultant on three projects: one looking at indication-based prescribing (United States Agency for Healthcare Research and Quality), a second to develop principles for conservative diagnosis (Gordon and Betty Moore Foundation), and a third deciding what drugs should be provided free of charge by general practitioners (Government of Canada, Ontario Supporting Patient Oriented Research Support Unit and the St Michael’s Hospital Foundation). He also received payments for being on a panel that discussed a pharmacare plan for Canada (Canadian Institute, a for-profit organization), a panel at the American Diabetes Association and for a talk at the Toronto Reference Library. He is currently a member of research groups that are receiving money from the Canadian Institutes of Health Research and the Australian National Health and Medical Research Council. He is member of the Foundation Board of Health Action International and the Board of Canadian Doctors for Medicare.

**References**

1. Food and Drugs Act, R.S.C., 1985, c. F-27. Health Canada; 2018 [Internet]. Available at: http://laws.justice.gc.ca/PDF/C.R.C._c._870.pdf [Accessed August 5, 2018].
2. Lexchin J, Mintzes B. A compromise too far: A review of Canadian cases of direct-to-consumer advertising regulation. Int J Risk Saf Med. 2014;26(4):213-25.
3. Law MR, Majumdar SR, Soumerai SB. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ. 2008;337:a1055.
4. Mackey TK. Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant
Regulation: Comment on “Trouble spots in online direct-to-consumer prescription drug promotion: A Content Analysis of FDA Warning Letters”. Int J Health Policy Manag. 2016;5(4):271-4.

5. Mackey TK, Cuomo RE, Liang BA. The rise of digital direct-to-consumer advertising: Comparison of direct-to-consumer advertising expenditure trends from publicly available data sources and global policy implications. BMC Health Serv Res. 2015;15(1):236.

6. Mintzes B. Advertising of prescription-only medicines to the public: Does evidence of benefit counterbalance harm? Ann Rev Public Health. 2012;33:259-77.

7. Huh J, Cude BJ. Is the information “fair and balanced” in direct-to-consumer prescription drug websites? J Health Commun. 2004;9(6):529-40.

8. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995-2002.

9. Brody H, Light DW. The inverse benefit law: how drug marketing undermines patient safety and public health. Am J Public Health. 2011;101(3):399-404.

10. Shnier A, Lexchin J, Mintzes B, Jutel A, Holloway K. Too few, too weak: conflict of interest policies at Canadian medical schools. PloS One. 2013;8(7):e68633.

11. Tonsaker T, Bartlett G, Trpkov C. Health information on the Internet: gold mine or minefield?. Can Fam Physician. 2014;60(5):407-8.

12. Statistics Canada. 2009 Canadian Internet use survey. Ottawa, ON: Government of Canada; 2011 [Internet]. Available at: https://www150.statcan.gc.ca/n1/daily-

quotidien/100510/dq100510a-eng.htm [Accessed August 5, 2018].

13. Morales A, Bebb RA, Manjoo P, Assimakopoulos P, Axler J, Collier C, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ. 2015;187(18):1369-77.

14. Layton JB, Li D, Meier CR, Sharpless JL, Stürmer T, Jick SS, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99(3):835-42.

15. Layton JB, Kim Y, Alexander GC, Emery SL. Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013. JAMA. 2017;317(11):1159-66.

16. Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-36.

17. Brax H, Fadlallah R, Al-Khaled L, Kahale LA, Nas H, El-Jardali F, Akl EA. Association between physicians’ interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis. PloS One. 2017 13;12(4):e0175493.

18. Gollust SE, Gray SW, Carere DA, Koenig BA, Lehmann LS, McGuire AL, Sharp RR, Spector-Bagdady K, Wang NA, Green RC, Roberts JS. Consumer Perspectives on Access to Direct-to-Consumer Genetic Testing: Role of Demographic Factors and the Testing Experience. The Milbank Quarterly. 2017;95(2):291-318.

19. Kravitz RL, Bell RA. Media, messages, and medication: strategies to reconcile what patients hear, what they want, and what they need from medications. BMC Med Inform Decis Mak. 2013;13(Suppl 3):55.